Non-Invasive Monitoring Systems (NIMU) 10-K 30 Oct 23 2023 FY Annual report Financial data

Cover

Cover - USD ($) $ in Millions	12 Months Ended
	Jul. 31, 2023	Oct. 30, 2023	Jan. 31, 2023
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Jul. 31, 2023
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--07-31
Entity File Number	000-13176
Entity Registrant Name	NON INVASIVE MONITORING SYSTEMS INC /FL/
Entity Central Index Key	0000720762
Entity Tax Identification Number	59-2007840
Entity Incorporation, State or Country Code	FL
Entity Address, Address Line One	4400 Biscayne Blvd.
Entity Address, Address Line Two	Suite 180
Entity Address, City or Town	Miami
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33137
City Area Code	(305)
Local Phone Number	575-4200
Title of 12(b) Security	Common Stock $0.01 par value per share
Trading Symbol	NIMU
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	true
Entity Public Float			$ 2.3
Entity Common Stock, Shares Outstanding		154,810,655
ICFR Auditor Attestation Flag	true
Document Financial Statement Error Correction [Flag]	false
Auditor Firm ID	274
Auditor Name	EisnerAmper LLP
Auditor Location	Fort Lauderdale, FL

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Jul. 31, 2023	Jul. 31, 2022
Current assets
Cash	$ 7	$ 15
Prepaid expenses	16	6
Total current assets	23	21
Total assets	23	21
Current liabilities
Accounts payable and accrued expenses	240	219
Current liabilities - discontinued operations	51	51
Total current liabilities	291	270
Total liabilities	635	434
Shareholders’ deficit
Series B Preferred Stock, par value $1.00 per share; 100 shares authorized, issued and outstanding; liquidation preference $10
Common Stock, par value $0.01 per share; 400,000,000 shares authorized; 154,810,655 shares issued and outstanding as of July 31, 2023 and 2022, respectively	1,548	1,548
Additional paid in capital	26,574	26,574
Accumulated deficit	(28,734)	(28,535)
Total shareholders’ deficit	(612)	(413)
Total liabilities and shareholders’ deficit	23	21
Related Party [Member]
Current liabilities
Notes payable – related parties	300	150
Accrued interest – related parties	$ 44	$ 14

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Jul. 31, 2023	Jul. 31, 2022
Preferred stock, shares authorized	1,000,000
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	400,000,000	400,000,000
Common stock, shares issued	154,810,655	154,810,655
Common stock, shares outstanding	154,810,655	154,810,655
Series B Preferred Stock [Member]
Preferred stock, par value	$ 1	$ 1
Preferred stock, shares authorized	100	100
Preferred stock, shares issued	100	100
Preferred stock, shares outstanding	100	100
Preferred stock, liquidation preference	$ 10	$ 10

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Jul. 31, 2023	Jul. 31, 2022
Operating costs and expenses
General and administrative	$ 169	$ 159
Total operating costs and expenses	169	159
Operating loss	(169)	(159)
Interest expense	(30)	(14)
Net loss	$ (199)	$ (173)
Weighted average number of common shares outstanding - basic	154,811	154,811
Weighted average number of common shares outstanding - diluted	154,811	154,811
Basic loss per common share	$ 0	$ 0
Diluted loss per common share	$ 0	$ 0

Consolidated Statements of Chan

Consolidated Statements of Changes in Shareholders' Deficit - USD ($) $ in Thousands	Preferred Stock [Member] Series B Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance, value at Jul. 31, 2021		$ 1,548	$ 26,574	$ (28,362)	$ (240)
Balance, shares at Jul. 31, 2021	100	154,810,655
Net loss				(173)	(173)
Balance, value at Jul. 31, 2022		$ 1,548	26,574	(28,535)	(413)
Balance, shares at Jul. 31, 2022	100	154,810,655
Net loss				(199)	(199)
Balance, value at Jul. 31, 2023		$ 1,548	$ 26,574	$ (28,734)	$ (612)
Balance, shares at Jul. 31, 2023	100	154,810,655

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2023	Jul. 31, 2022
Operating activities
Net loss	$ (199)	$ (173)
Changes in operating assets and liabilities
Prepaid expenses	(10)	(2)
Accounts payable and accrued expenses	21	(29)
Net cash used in operating activities	(158)	(190)
Financing activities
Proceeds from notes payable – related parties	150	150
Net cash provided by financing activities	150	150
Net decrease in cash	(8)	(40)
Cash, beginning of year	15	55
Cash, end of year	7	15
Related Party [Member]
Changes in operating assets and liabilities
Accrued interest – related parties	$ 30	$ 14

ORGANIZATION AND BUSINESS

ORGANIZATION AND BUSINESS	12 Months Ended
	Jul. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
ORGANIZATION AND BUSINESS	1. ORGANIZATION AND BUSINESS Organization. ® Business. Going Concern. 0.2 28.7 7,000 268,000 On August 15, 2023, the Company entered into a Promissory Note in the principal amount of $ 200,000 10 11 The Company is seeking potential mergers, acquisitions and strategic collaborations. There is no assurance that the Company will be successful in this regard, and, if not successful, that it will be able to continue its business activities. The accompanying consolidated financial statements do not include any adjustments that might be necessary from the outcome of this uncertainty. Discontinued Operations. Accordingly, the Company determined that the assets and liabilities met the discontinued operations criteria in Accounting Standards Codification 205-20-45 and were classified as discontinued operations at May 3, 2019. See Discontinued Operations Note 3.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Jul. 31, 2023
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Consolidation Discontinued Operations Use of Estimates Cash and Cash Equivalents 7,000 15,000 Income Taxes The Company files its tax returns as prescribed by the laws of the jurisdictions in which it operates. Tax years ranging from 2019 to 2023 remain open to examination by various taxing jurisdictions as the statute of limitations has not expired. The net operating losses are generally subject to examination up to three years after the utilization of such losses. It is the Company’s policy to include income tax interest and penalty expense in its tax provision. Fair Value of Financial Instruments Loss Contingencies Related Parties Recent Accounting Pronouncements

DISCONTINUED OPERATIONS

DISCONTINUED OPERATIONS	12 Months Ended
	Jul. 31, 2023
Discontinued Operations and Disposal Groups [Abstract]
DISCONTINUED OPERATIONS	3. DISCONTINUED OPERATIONS On May 3, 2019, the Company exchanged its inventory for forgiveness of accrued unpaid rent. Concurrent with the exchange management with the appropriate level of authority determined to discontinue the operations of the product segment. The detail of the consolidated balance sheets for discontinued operations is as stated below (in thousands): SCHEDULE OF BALANCE SHEETS OF DISCONTINUED OPERATIONS As of July 31, 2023 As of July 31, 2022 Current liabilities – discontinued operations Accounts payable and accrued expenses $ 51 $ 51 Total current liabilities – discontinued operations 51 51 Total liabilities – discontinued operations $ 51 $ 51

SHAREHOLDERS_ EQUITY

SHAREHOLDERS’ EQUITY	12 Months Ended
	Jul. 31, 2023
Equity [Abstract]
SHAREHOLDERS’ EQUITY	4. SHAREHOLDERS’ EQUITY The Company has one class of Preferred Stock. Holders of Series B Preferred Stock are entitled to vote with the holders of common stock as a single class on all matters. We are currently authorized to issue an aggregate of 401,000,000 400,000,000 1,000,000 Series B Preferred Stock is not redeemable by the Company and has a liquidation value of $ 100 10 No The Company did no the years ended July 31, 2023 and 2022.

BASIC AND DILUTED LOSS PER SHAR

BASIC AND DILUTED LOSS PER SHARE	12 Months Ended
	Jul. 31, 2023
Earnings Per Share [Abstract]
BASIC AND DILUTED LOSS PER SHARE	5. BASIC AND DILUTED LOSS PER SHARE Basic net loss per common share is computed by dividing net loss attributable to common shareholders by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed giving effect to all dilutive potential common shares that were outstanding during the period. Diluted potential common shares consist of incremental shares issuable upon conversion of preferred stock. In computing diluted net loss per share for the years ended July 31, 2023 and 2022, no

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	12 Months Ended
	Jul. 31, 2023
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	6. RELATED PARTY TRANSACTIONS Dr. Hsiao and directors Dr. Frost and Rao Uppaluri and former director Steve Rubin are each stockholders, current or former officers and/or directors or former directors of Asensus Surgical, Inc. (formerly TransEnterix, Inc.) (“Asensus”), a publicly-traded medical device company. Dr. Frost is a director and over 5% shareholder of Cocrystal Pharma, Inc. (“Cocrystal Pharma”), a clinical stage Nasdaq listed biotechnology company 0 400 no The Company signed a five year 10 December 31, 2012 1,250 0 no 0 The Company is under common control with multiple entities and the existence of that control could result in operating results or financial position of each individual entity significantly different from those that would have been obtained if the entities were autonomous. One of those related parties, OPKO Health, Inc. (“OPKO”) and the Company are under common control and OPKO has a one percent ownership interest in the Company that OPKO has accounted for as an equity method investment due to the ability to significantly influence the Company.

NOTES PAYABLE _ RELATED PARTY

NOTES PAYABLE – RELATED PARTY	12 Months Ended
	Jul. 31, 2023
Debt Disclosure [Abstract]
NOTES PAYABLE – RELATED PARTY	7. NOTES PAYABLE – RELATED PARTY On September 16, 2022, the Company entered into two Promissory Notes in the principal amount of $ 75,000 11 July 31, 2025 On October 4, 2021, the Company entered into two Promissory Notes in the principal amount of $ 75,000 11 July 31, 2025

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Jul. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	8. COMMITMENTS AND CONTINGENCIES Leases The Company was under an operating lease agreement for our corporate office space that expired in 2012

ACCOUNTS PAYABLE AND ACCRUED EX

ACCOUNTS PAYABLE AND ACCRUED EXPENSES	12 Months Ended
	Jul. 31, 2023
Payables and Accruals [Abstract]
ACCOUNTS PAYABLE AND ACCRUED EXPENSES	9. ACCOUNTS PAYABLE AND ACCRUED EXPENSES Accounts payable and accrued expenses from continuing operations are summarized in the following table (in thousands): SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES July 31, 2023 July 31, 2022 Accounts payable $ 209 $ 203 Accrued redemption 10 10 Accrued other 21 6 Total $ 240 $ 219

INCOME TAXES

INCOME TAXES	12 Months Ended
	Jul. 31, 2023
Income Tax Disclosure [Abstract]
INCOME TAXES	10. INCOME TAXES The Company accounts for income taxes using the asset and liability method. Pursuant to this method, deferred tax assets and liabilities are established for the differences between the financial reporting and the tax bases of the Company’s assets and liabilities and net operating loss carryforwards at enacted tax rates expected to be in effect when such amounts are realized or settled. A valuation allowance related to deferred tax assets is recorded when it is more likely than not that some portion or all of the deferred tax assets will not be realized. The accounting for uncertain tax positions guidance under ASC 740 requires that we recognize the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent The Company files its tax returns in the U.S. federal jurisdiction and with U.S. states. The Company is subject to tax audits in all jurisdictions for which it files tax returns. Tax audits by their very nature are often complex and can require several years to complete. There are currently no tax audits that have commenced with respect to income tax or any other returns in any jurisdiction. Tax years ranging from 2019 to 2023 remain open to examination by various taxing jurisdictions as the statute of limitations has not expired. Because the Company is carrying forward income tax attributes, such as net operating losses and tax credits from 2018 and earlier tax years, these attributes can still be audited when utilized on returns filed in the future. It is the Company’s policy to include income tax interest and penalties expense in its tax provision. The difference between income taxes at the statutory federal income tax rate of 21 SCHEDULE OF FEDERAL INCOME TAX RATE AND INCOME TAXES July 31, 2023 % July 31, 2022 % Income tax benefit at the federal statutory rate from continuing operations $ (42 ) 21.0 $ (36 ) 21.0 State income taxes, net of effect of federal taxes (9 ) 4.5 (7 ) 4.3 Expired net operating losses 364 (182.8 ) 282 (164.3 ) Change in valuation allowance (313 ) 157.3 (239 ) 139.0 Total $ - - $ - - The tax effects of temporary differences that give rise to significant portions of the deferred tax assets consist of the following (in thousands): SCHEDULE OF DEFERRED TAX ASSETS July 31, 2023 July 31, 2022 Federal and State net operating loss $ 3,768 $ 4,081 Foreign net operating loss 18 18 Other 3 3 Deferred tax assets gross,total 3,789 4,102 Less: Valuation allowance (3,789 ) (4,102 ) Net deferred tax asset $ - $ - At July 31, 2023, the Company had available Federal and State net operating loss carry forwards of approximately $ 14.8 0.1 Net operating loss carry forwards generated in 2019 and later years never expire reduce taxable income by 80 percent A valuation allowance is required to reduce the deferred tax assets reported if, based on the weight of the evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. After consideration of all the evidence, both positive and negative, management has determined that a full $ 3.8 4.1 313,000 239,000 no

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Jul. 31, 2023
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	11. SUBSEQUENT EVENTS On August 15, 2023, the Company entered into a Promissory Note in the principal amount of $ 200,000 11 July 31, 2025

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Jul. 31, 2023
Accounting Policies [Abstract]
Consolidation	Consolidation
Discontinued Operations	Discontinued Operations
Use of Estimates	Use of Estimates
Cash and Cash Equivalents	Cash and Cash Equivalents 7,000 15,000
Income Taxes	Income Taxes The Company files its tax returns as prescribed by the laws of the jurisdictions in which it operates. Tax years ranging from 2019 to 2023 remain open to examination by various taxing jurisdictions as the statute of limitations has not expired. The net operating losses are generally subject to examination up to three years after the utilization of such losses. It is the Company’s policy to include income tax interest and penalty expense in its tax provision.
Fair Value of Financial Instruments	Fair Value of Financial Instruments
Loss Contingencies	Loss Contingencies
Related Parties	Related Parties
Recent Accounting Pronouncements	Recent Accounting Pronouncements

DISCONTINUED OPERATIONS (Tables

DISCONTINUED OPERATIONS (Tables)	12 Months Ended
	Jul. 31, 2023
Discontinued Operations and Disposal Groups [Abstract]
SCHEDULE OF BALANCE SHEETS OF DISCONTINUED OPERATIONS	The detail of the consolidated balance sheets for discontinued operations is as stated below (in thousands): SCHEDULE OF BALANCE SHEETS OF DISCONTINUED OPERATIONS As of July 31, 2023 As of July 31, 2022 Current liabilities – discontinued operations Accounts payable and accrued expenses $ 51 $ 51 Total current liabilities – discontinued operations 51 51 Total liabilities – discontinued operations $ 51 $ 51

ACCOUNTS PAYABLE AND ACCRUED _2

ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)	12 Months Ended
	Jul. 31, 2023
Payables and Accruals [Abstract]
SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES	Accounts payable and accrued expenses from continuing operations are summarized in the following table (in thousands): SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES July 31, 2023 July 31, 2022 Accounts payable $ 209 $ 203 Accrued redemption 10 10 Accrued other 21 6 Total $ 240 $ 219

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Jul. 31, 2023
Income Tax Disclosure [Abstract]
SCHEDULE OF FEDERAL INCOME TAX RATE AND INCOME TAXES	SCHEDULE OF FEDERAL INCOME TAX RATE AND INCOME TAXES July 31, 2023 % July 31, 2022 % Income tax benefit at the federal statutory rate from continuing operations $ (42 ) 21.0 $ (36 ) 21.0 State income taxes, net of effect of federal taxes (9 ) 4.5 (7 ) 4.3 Expired net operating losses 364 (182.8 ) 282 (164.3 ) Change in valuation allowance (313 ) 157.3 (239 ) 139.0 Total $ - - $ - -
SCHEDULE OF DEFERRED TAX ASSETS	The tax effects of temporary differences that give rise to significant portions of the deferred tax assets consist of the following (in thousands): SCHEDULE OF DEFERRED TAX ASSETS July 31, 2023 July 31, 2022 Federal and State net operating loss $ 3,768 $ 4,081 Foreign net operating loss 18 18 Other 3 3 Deferred tax assets gross,total 3,789 4,102 Less: Valuation allowance (3,789 ) (4,102 ) Net deferred tax asset $ - $ -

ORGANIZATION AND BUSINESS (Deta

ORGANIZATION AND BUSINESS (Details Narrative) - USD ($)		12 Months Ended
	Aug. 15, 2023	Jul. 31, 2023	Jul. 31, 2022
Short-Term Debt [Line Items]
Net losses from continuing operations		$ 200,000	$ 200,000
Accumulated deficit		28,734,000	$ 28,535,000
Cash		7,000
Working capital deficit		$ 268,000
Subsequent Event [Member] | Frost Gamma [Member]
Short-Term Debt [Line Items]
Beneficial ownership percentage	10%
Frost Gamma Note [Member] | Subsequent Event [Member]
Short-Term Debt [Line Items]
Promissory notes, principal amount	$ 200,000
Frost Gamma Note [Member] | Subsequent Event [Member] | Dr. Phillip Frost [Member]
Short-Term Debt [Line Items]
Interest rate payable	11%

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	Jul. 31, 2023	Jul. 31, 2022
Accounting Policies [Abstract]
Cash at bank	$ 7,000	$ 15,000

SCHEDULE OF BALANCE SHEETS OF D

SCHEDULE OF BALANCE SHEETS OF DISCONTINUED OPERATIONS (Details) - USD ($) $ in Thousands	Jul. 31, 2023	Jul. 31, 2022
Current liabilities – discontinued operations
Accounts payable and accrued expenses	$ 51	$ 51
Total current liabilities – discontinued operations	51	51
Total liabilities – discontinued operations	$ 51	$ 51

SHAREHOLDERS_ EQUITY (Details N

SHAREHOLDERS’ EQUITY (Details Narrative) - USD ($)	12 Months Ended
	Jul. 31, 2023	Jul. 31, 2022
Class of Stock [Line Items]
Capital units, authorized	401,000,000
Common stock, shares authorized	400,000,000	400,000,000
Preferred stock, designated shares	1,000,000
Dividends, preferred stock	$ 0	$ 0
Stock issued during the period	0	0
Series B Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, designated shares	100	100
Preferred stock liquidation preference, per share value	$ 100
Dividends payable amount per share	$ 10

BASIC AND DILUTED LOSS PER SH_2

BASIC AND DILUTED LOSS PER SHARE (Details Narrative) - shares	12 Months Ended
	Jul. 31, 2023	Jul. 31, 2022
Earnings Per Share [Abstract]
Antidilutive securities excluded from computation of earnings per share, amount	0	0

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)		1 Months Ended	12 Months Ended
	Jan. 01, 2008	Feb. 29, 2016	Jul. 31, 2023	Jul. 31, 2022
Related Party Transaction [Line Items]
Accounts payable, related parties			$ 209,000	$ 203,000
Dr. Phillip Frost [Member]
Related Party Transaction [Line Items]
Lease term	5 years
Beneficial ownership percentage	10%
Lease expired date	Dec. 31, 2012
Rental payments	$ 1,250	$ 0	0	0
Rent expense			0	$ 0
Cost Sharing Arrangement [Member] | Cocrystal Pharma Inc [Member]
Related Party Transaction [Line Items]
Related party transaction, description				Dr. Frost is a director and over 5% shareholder of Cocrystal Pharma, Inc. (“Cocrystal Pharma”), a clinical stage Nasdaq listed biotechnology company
Cost Sharing Arrangement [Member] | Asensus Surgical Inc [Member]
Related Party Transaction [Line Items]
Costs and expenses of related party			0	$ 400
Accounts payable, related parties			$ 0	$ 0

NOTES PAYABLE _ RELATED PARTY (

NOTES PAYABLE – RELATED PARTY (Details Narrative) - Two Promissory Notes [Member] - USD ($)	Sep. 16, 2022	Oct. 04, 2021
Short-Term Debt [Line Items]
Note and security agreement, description	the Company entered into two Promissory Notes in the principal amount of $75,000 each with Frost Gamma Investments Trust (the “2022 Frost Gamma Note”), a trust controlled by Dr. Phillip Frost, a current director, and with Jane Hsiao, Ph.D., the Company’s Chairman and Interim CEO (the “2022 Hsiao Note”), both which beneficially own in excess of 10% of NIMS’ common stock. The interest rate payable by NIMS on the 2022 Frost Gamma Note and 2022 Hsiao Note is 11% per annum, payable on the Maturity Date of July 31, 2025, as amended on August 15, 2023. The 2022 Frost Gamma Note and 2022 Hsiao Note may be prepaid in advance of the Maturity Date without penalty	the Company entered into two Promissory Notes in the principal amount of $75,000 each with Frost Gamma Investments Trust (the “2021 Frost Gamma Note”), a trust controlled by Dr. Phillip Frost, a current director, and with Jane Hsiao, Ph.D., the Company’s Chairman and Interim CEO (the “2021 Hsiao Note”), both which beneficially own in excess of 10% of NIMS’ common stock. The interest rate payable by NIMS on the 2021 Frost Gamma Note and 2021 Hsiao Note is 11% per annum, payable on the Maturity Date of July 31, 2025, as amended on August 15, 2023. The 2021 Frost Gamma Note and 2021 Hsiao Note may be prepaid in advance of the Maturity Date without penalty
Promissory notes, principal amount	$ 75,000	$ 75,000
Interest rate payable, percentage	11%	11%
Maturity date	Jul. 31, 2025	Jul. 31, 2025

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Narrative)	12 Months Ended
	Jul. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Lease expiration, date	2012

SCHEDULE OF ACCOUNTS PAYABLE AN

SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) - USD ($) $ in Thousands	Jul. 31, 2023	Jul. 31, 2022
Payables and Accruals [Abstract]
Accounts payable	$ 209	$ 203
Accrued redemption	10	10
Accrued other	21	6
Total	$ 240	$ 219

SCHEDULE OF FEDERAL INCOME TAX

SCHEDULE OF FEDERAL INCOME TAX RATE AND INCOME TAXES (Details) - USD ($) $ in Thousands	12 Months Ended
	Jul. 31, 2023	Jul. 31, 2022
Income Tax Disclosure [Abstract]
Income tax benefit at the federal statutory rate from continuing operations	$ (42)	$ (36)
Income tax benefit at the federal statutory rate from continuing operations, percent	21%	21%
State income taxes, net of effect of federal taxes	$ (9)	$ (7)
State income taxes, net of effect of federal taxes, rate	4.50%	4.30%
Expired net operating losses	$ 364	$ 282
Expired net operating losses, rate	(182.80%)	(164.30%)
Change in valuation allowance	$ (313)	$ (239)
Change in valuation allowance, rate	157.30%	139%
Total
Total Percentage

SCHEDULE OF DEFERRED TAX ASSETS

SCHEDULE OF DEFERRED TAX ASSETS (Details) - USD ($) $ in Thousands	Jul. 31, 2023	Jul. 31, 2022
Income Tax Disclosure [Abstract]
Federal and State net operating loss	$ 3,768	$ 4,081
Foreign net operating loss	18	18
Other	3	3
Deferred tax assets gross,total	3,789	4,102
Less: Valuation allowance	(3,789)	(4,102)
Net deferred tax asset

INCOME TAXES (Details Narrative

INCOME TAXES (Details Narrative) - USD ($)	12 Months Ended
	Jul. 31, 2023	Jul. 31, 2022
Operating Loss Carryforwards [Line Items]
Income tax likelihood percentage description	greater than 50 percent
Statutory federal income tax rate	21%	21%
Operating loss carryforwards expire, description	Net operating loss carry forwards generated in 2019 and later years never expire
Reduce taxable income percentage description	reduce taxable income by 80 percent
Deferred tax assets, valuation allowance	$ 3,789,000	$ 4,102,000
Decrease in valuation allowance	313,000	239,000
Income taxes paid	0	$ 0
Fedral And State Tax Authority [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	14,800,000
Foreign Tax Authority [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	$ 100,000

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - Promissory Note [Member] - Subsequent Event [Member]	Aug. 15, 2023 USD ($)
Subsequent Event [Line Items]
Note and security agreement, description	the Company entered into a Promissory Note in the principal amount of $200,000 with Frost Gamma Investments Trust (the “2023 Frost Gamma Note”), a trust controlled by Dr. Phillip Frost, which beneficially owns in excess of 10% of the Company’s common stock. The interest rate payable by NIMS on the 2023 Frost Gamma Note is 11% per annum, payable on the maturity date of July 31, 2025 (the “Maturity Date”). The 2023 Frost Gamma Note may be prepaid in advance of the Maturity Date without penalty
Interest rate payable, percentage	11%
Maturity date	Jul. 31, 2025
Dr. Phillip Frost [Member]
Subsequent Event [Line Items]
Promissory notes, principal amount	$ 200,000